Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$1.41
+1.4%
$2.43
$1.38
▼
$6.44
$270.48M0.164.13 million shs4.30 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,352.18
-2.2%
$1,263.45
$850.51
▼
$1,475.25
$1.30T0.43.08 million shs3.20 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.89
-1.4%
$39.69
$35.12
▼
$64.16
$176.05B0.712.77 million shs17.57 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.44%-12.42%-38.70%-54.66%-69.28%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.08%-5.66%+5.18%+7.55%+28.91%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.52%-4.36%-1.11%-16.92%-20.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$1.41
+1.4%
$2.43
$1.38
▼
$6.44
$270.48M0.164.13 million shs4.30 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,352.18
-2.2%
$1,263.45
$850.51
▼
$1,475.25
$1.30T0.43.08 million shs3.20 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.89
-1.4%
$39.69
$35.12
▼
$64.16
$176.05B0.712.77 million shs17.57 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.44%-12.42%-38.70%-54.66%-69.28%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.08%-5.66%+5.18%+7.55%+28.91%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.52%-4.36%-1.11%-16.92%-20.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.70
Moderate Buy$14.33916.55% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.005.16% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$59.4452.84% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,600.00
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Altimmune, Inc. stock logo
ALT
Altimmune
DowngradeSell (D-) ➝ Sell (E+)
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/13/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Reiterated RatingMarket Outperform
11/13/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Reiterated RatingBuy
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$40K6,859.30N/AN/A$2.28 per share0.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B19.52$24.58 per share55.01$42.81 per share31.59
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B3.71$4.62 per share8.41$7.51 per share5.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$0.72N/AN/AN/AN/A-29.26%-25.48%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8143.8926.661.6531.90%86.76%22.03%2/3/2027 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$3.9710.1411.271.3633.99%53.52%19.49%2/3/2027 (Estimated)

Latest LLY, NVO, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.1325-$0.15-$0.0175-$0.15$0.00 millionN/A
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.51%+15.18%22.46%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.822.11%+21.74%20.65%N/A

Latest LLY, NVO, and ALT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.08
23.93
23.93
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.54
0.84
0.64

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
1.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
57194.59 million191.48 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk's Pipeline Momentum Meets a Widening Regulatory Front
Novo Nordisk Balances Pipeline Wins Against a Harder Road in China
Novo Nordisk: The Worst May Be Behind
Novo Nordisk (NVO) Stock May Be Undervalued On Raised 2026 Outlook
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$1.41 +0.02 (+1.44%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$1.41 0.00 (0.00%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,352.18 -30.57 (-2.21%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$1,344.46 -7.73 (-0.57%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$38.89 -0.54 (-1.37%)
Closing price 11/19/2026
Extended Trading
$38.74 -0.15 (-0.40%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.